Depression and suicidal ideation and behavior are reported for monoclonal antibodies (mAbs), especially for mAbs used for the treatment of patients with autoimmune diseases that suppress the immune system.

The present study provides important knowledge for future research on the relation between the different inflammatory factors and the occurrence of depression and suicidal ideation and behavior. Future studies should focus on, amongst others, indications for use, and population characteristics to characterize and quantify this potential risk.